Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2012-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2012.04.121PMID 22632933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010

  2011cited by this paper
• How well can fragments explore accessed chemical space? A case study from heat shock protein 90.

  2011cited by this paper
• The benefits of constructing leads from fragment hits.

  2011cited by this paper
• 240TH ACS NATIONAL MEETING: BOSTON, Aug. 22–26

  2010cited by this paper
• Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

  2010cited by this paper
• STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.

  2010cited by this paper
• Discovery and development of heat shock protein 90 inhibitors.

  2009cited by this paper
• CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

  2009cited by this paper
• Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.

  2008cited by this paper
• The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

  2008cited by this paper
• 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

  2007cited by this paper
• N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.

  2007cited by this paper
• Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.

  2006cited by this paper
• Structure and mechanism of the Hsp90 molecular chaperone machinery.

  2006cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Ligand efficiency indices as guideposts for drug discovery.

  2005cited by this paper
• Crystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles

  2005cited by this paper
• Structure-based discovery of a new class of Hsp90 inhibitors.

  2005cited by this paper
• Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Therapeutic and diagnostic implications of Hsp90 activation

  2004cited by this paper
• Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

  2004cited by this paper
• Hsp90: the vulnerable chaperone.

  2004cited by this paper
• Ligand efficiency: a useful metric for lead selection.

  2004cited by this paper
• Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

  2004cited by this paper
• Pathways of chaperone-mediated protein folding in the cytosol

  2004cited by this paper
• Molecular chaperones and the stress of oncogenesis

  2004cited by this paper
• A 'rule of three' for fragment-based lead discovery?

  2003cited by this paper
• Development of radicicol analogues.

  2003cited by this paper
• Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1

  2003cited by this paper
• HSP90 as a new therapeutic target for cancer therapy: the story unfolds

  2002cited by this paper
• Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.

  2000cited by this paper
• A hybrid approach for addressing ring flexibility in 3D database searching

  1997cited by this paper
• Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

  1997cited by this paper
• A fast flexible docking method using an incremental construction algorithm.

  1996cited by this paper

• Combined In-Solution Fragment Screening and Crystallographic Binding-Mode Analysis with a Two-Domain Hsp70 Construct.

  2024cites this paper
• Worth the Weight: Sub-Pocket EXplorer (SubPEx), a Weighted Ensemble Method to Enhance Binding-Pocket Conformational Sampling

  2023cites this paper
• A comprehensive review on the indazole based derivatives as targeted anticancer agents

  2023cites this paper
• Worth the weight: Sub-Pocket EXplorer (SubPEx), a weighted-ensemble method to enhance binding-pocket conformational sampling

  2023cites this paper
• Indazole Derivatives Effective against Gastrointestinal Diseases.

  2021cites this paper
• Advances in Docking-Based Drug Design for Microbial and Cancer Drug Targets

  2021cites this paper
• Plant Coumarins: XVII. Synthesis and Transformations of 7-Hydroxy-2-oxo-2H-chromene-6-carboxamides

  2019cites this paper
• Indazoles: Synthesis and Bond-Forming Heterocyclization

  2018cites this paper
• Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors.

  2018cites this paper
• Palladium(0)-Catalysed Carbonylative Multicomponent Reactions : Synthesis of Heterocycles and the Application of Quinolinyl Pyrimidines as Enzyme Inhibitors

  2017cites this paper
• On the Interactions of Fused Pyrazole Derivative with Selected Amino Acids: DFT Calculations

  2017cites this paper
• Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.

  2016cites this paper
• New 1H-Benzo[f]indazole-4,9-diones Conjugated with C-Protected Amino Acids and Other Derivatives: Synthesis and in Vitro Antiproliferative Evaluation

  2015cites this paper
• Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future

  2014cites this paper
• Hsp90 Inhibitors, Part 1: Definition of 3-D QSAutogrid/R Models as a Tool for Virtual Screening

  2014cites this paper
• Multitarget fragment‐based design of novel inhibitors for AChE and SSAO/VAP‐1 enzymes

  2013cites this paper
• Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).

  2013cites this paper
• Protein crystallography and fragment-based drug design.

  2013cites this paper
• Subpocket Analysis Method for Fragment-Based Drug Discovery

  2013cites this paper
• Computational tools for in silico fragment-based drug design.

  2012cites this paper